Skip to main content
FDA approves Reblozyl for thalassemia-related anemia in adults

The FDA has approved the use of Reblozyl, or luspatercept-aamt, to treat anemia in adult patients with beta thalassemia who need frequent red blood cell transfusions, with Acceleron Pharma and partner Celgene promoting the product jointly in the US.

Full Story: